Cargando…
A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects
Immune checkpoint inhibitors, such as ipilimumab and nivolumab, reverse the imbalance of antitumor self-tolerance and enhance T-cell responses. Currently, ipilimumab and nivolumab have a reported therapeutic impact on unresectable or metastatic melanomas; however, they also induce immune-related adv...
Autores principales: | Utsunomiya, Akira, Oyama, Noritaka, Iino, Shiro, Baba, Natsuki, Chino, Takenao, Utsunomiya, Natsuko, Hasegawa, Minoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836162/ https://www.ncbi.nlm.nih.gov/pubmed/29515387 http://dx.doi.org/10.1159/000485910 |
Ejemplares similares
-
A cysteine proteinase inhibitor ALLN alleviates bleomycin-induced skin and lung fibrosis
por: Kasamatsu, Hiroshi, et al.
Publicado: (2023) -
First Report of Erythema Multiforme Minor Caused by Raloxifene Hydrochloride
por: Norimatsu, Yurie, et al.
Publicado: (2021) -
Development of Nivolumab/Ipilimumab-Associated Autoimmune Nephritis during Steroid Therapy
por: Gebauer, Ellen, et al.
Publicado: (2021) -
The compound LG283 inhibits bleomycin-induced skin fibrosis via antagonizing TGF-β signaling
por: Utsunomiya, Akira, et al.
Publicado: (2022) -
Intravenous Immunoglobulin Therapy-Induced Erythema Multiforme in a Patient with Chronic Lymphocytic Leukemia
por: Konovalova, Angelina, et al.
Publicado: (2023)